These estrogen-mediated factors can enhance the effects of cancer therapy in women by reducing the activation of the NQO1 transcription factor NRF2 and regulating other antioxidant-related transcription factors via the NRF2 pathway (Kim, 2022). The gene discussed is NQO1; the disease is cancer.